Drug Profile
Research programme: anticancer immunotherapies - Samyang Pharmaceuticals
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Samyang Biopharmaceuticals Corporation
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Immune checkpoint protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer